A New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®)
Dexamethasone implant, 0,7 mg (Ozurdex, Allergan, Inc., Irvine, CA, USA), is drug mostly used in the treatment of the diabetic macular edema and edema related to retinal vein occlusion. By reporting this case we aimed to report a new side effect of 0.7 mg intravitreal dexamethasone implant that has...
Main Authors: | Erdem Eris, Gurkan Erdogan, Irfan Perente, Gokhan Demir, Burcin Kepez Yildiz, Ebru Demet Aygit |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | Case Reports in Ophthalmological Medicine |
Online Access: | http://dx.doi.org/10.1155/2017/6369085 |
Similar Items
-
Intravitreal Dexamethasone Implant (Ozurdex) in Coats' Disease
by: Ali Osman Saatci, et al.
Published: (2013-09-01) -
Acute retinal necrosis following intravitreal dexamethasone (Ozurdex®) implant
by: Murat Kucukevcilioglu, et al.
Published: (2015-04-01) -
Modified insertion technique for a sustained-release dexamethasone intravitreal implant (Ozurdex®)
by: Daniel H. Lee, et al.
Published: (2020-09-01) -
Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa
by: Nurgül Örnek, et al.
Published: (2016-08-01) -
Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients
by: Hatice Ayhan Güler, et al.
Published: (2018-09-01)